ProCE Banner Activity

Frontline Immune Checkpoint Inhibitor Therapy in Advanced Head and Neck Cancer

Slideset Download
Downloadable slides review the optimal use of immune checkpoint inhibitors in the frontline setting in patients with advanced metastatic head and neck cancer.

Released: November 10, 2020

Expiration: November 09, 2021

No longer available for credit.

Share

Faculty

Barbara Burtness

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Yale School of Medicine
Chief Translational Research Officer
Division Chief
Head and Neck/Sarcoma Oncology
Co-leader
Developmental Therapeutics Program
Director
Yale Head and Neck SPORE
Yale Cancer Center
Chair
ECOG-ACRIN Cancer Research Group
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Yale School of Medicine
Chief Translational Research Officer
Division Chief
Head and Neck/Sarcoma Oncology
Co-leader
Developmental Therapeutics Program
Director
Yale Head and Neck SPORE
Yale Cancer Center
Chair
ECOG-ACRIN Cancer Research Group
New Haven, Connecticut

Barbara Burtness, MD, has disclosed that she has received consulting fees from Aduro, ALX Oncology, Celgene, Chemotherapy Advisory, Cue Biopharma, Debio Pharm, GlaxoSmithKline, Io Biotech, Kura, Macrogenics, Maverick, Merck, Nanobiotix, and Rakuten.